Information  X 
Enter a valid email address

Creo Medical Group (CREO)

  Print      Mail a friend

Thursday 21 March, 2019

Creo Medical Group

Notice of results and investor briefing

RNS Number : 4892T
Creo Medical Group PLC
21 March 2019
 

 

                                                                                               Creo Medical Group plc

("Creo" or the "Company")

 

Notice of results and investor briefing

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, will announce its final results for the 18 month period to 31 December 2018 on Friday 5 April 2019.

 

Investor briefing

A briefing for investors will take place on Tuesday 9 April 2019 at the Brand Exchange, 3 Birchin Lane, EC3V 9BW at 5.15pm for a 5.30pm start and will be followed by refreshments. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email [email protected]

 

- Ends -

 

For further information please contact:

 

Creo Medical Group plc

 

Richard Rees (CFO)

+44 (0)129 160 6005

 

 

Cenkos Securities

+44 (0)20 7397 8900

Stephen Keys / Mark Connelly (NOMAD)

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893

Helen Cresswell

Mob: +44 (0)7841 917 679

 

About Creo Medical

 

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy.  Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation.  This technology provides clinicians with flexible, accurate and controlled surgical solutions.

 

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs.  The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures.  The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

 

For more information about Creo Medical please see our website, investors.creomedical.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORZMGZFKGRGLZM

a d v e r t i s e m e n t